Luiza Ianny de Lima and João Paulo Figueiró Longo*

Institute of Biological Science - IB, Genetics and Morphology Department, University of Brasília - UnB, Brazil

*Corresponding Author: João Paulo Figueiró Longo, Institute of Biological Science - IB, Genetics and Morphology Department, University of Brasília - UnB, Brazil.

Received: May 25, 2021; Published: June 03, 2021

Abstract

  As a prospect for the next years, we believe that nanomedicine could be widely translated to clinical practices based on chemotherapy reduction in toxicity provided by the technology. Oncology patients, who are the core point of all this process, can greatly benefit from adopting nanomedicines. In this way, several conventional chemotherapeutical drugs could be used in their nano-based generic form, with lower related toxicity, providing better results for patients. For this approach, doctors could adopt simple and easy production nanocarriers early to reduce the risks. During this process, new innovations with more complex technical structures could be added as confidence in nanomedicine advances.

Keywords: Nanomedicine; Toxicity; Clinical Translation

References

1. van der Meel R., et al. “Smart cancer nanomedicine”. Nature Nanotechnology 14 (2019): 1007-1017.
2. Chan W C W. “Nanomedicine 2.0”. Accounts of Chemical Research 50 (2017): 627-632.
3. Matsumura Y and Maeda H. “A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs”. Cancer Research 46 (1986): 6387-6392.
4. Nakamura Y., et al. “Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer?” Bioconjugate Chemistry 27 (2016): 2225-2238.
5. Ngoune R., et al. “Accumulating nanoparticles by EPR: A route of no return”. Journal of Controlled Release 238 (2016): 58-70.
6. Torchilin V. “Tumor delivery of macromolecular drugs based on the EPR effect”. Advanced Drug Delivery Reviews 63 (2011): 131-135.
7. F Longo., et al. “Nanomedicine for cutaneous tumors - lessons since the successful treatment of the Kaposi sarcoma”. Nanomedicine 13 (2018): 2957-2959.
8. Longo J P F., et al. “Prevention of distant lung metastasis after photodynamic therapy application in a breast cancer tumor model”. Journal of Biomedical Nanotechnology 12 (2016): 689-699.
9. Wilhelm S., et al. “Analysis of nanoparticle delivery to tumours”. Nature Reviews Materials 1 (2016): 1-12 (2016).
10. Arami H., et al. “Nanomedicine for spontaneous brain tumors: a companion clinical trial”. ACS Nano 13 (2019): 2858-2869.
11. Rocha M S T., et al. “Photodynamic therapy for cutaneous hemangiosarcoma in dogs”. Photodiagnosis and Photodynamic Therapy 27 (2019): 39-43.
12. Radicchi M A., et al. “Lipid nanoemulsion passive tumor accumulation dependence on tumor stage and anatomical location: a new mathematical model for in vivo imaging biodistribution studies”. Journal of Materials Chemistry B 6 (2018): 7306-7316.
13. Sindhwani S., et al. “The entry of nanoparticles into solid tumours”. Nature Material 19 (2020): 566-575.
14. dos Santos Câmara A L., et al. “Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model”. Nanomedicine 12 (2017): 1751-1765.

Citation

Citation: Luiza Ianny de Lima and João Paulo Figueiró Longo. “Guiding Aspects Translating Nanomedicine". Acta Scientific Pharmaceutical Sciences 5.7 (2020): 30-33.